Li HY, et al. - Whether cyclosporine A (CsA) affords a safe and effective treatment option for patients with steroid-resistant nephrotic syndrome (SRNS), was investigated in this meta-analysis. Researchers identified the relevant studies from the Cochrane Library and PubMed. In the therapeutic regimen of CsA compared with placebo/nontreatment, high values of complete remission, total remission (TR), and low values of proteinuria, serum creatinine, and plasma cholesterol were detected in the CsA group vs those in the placebo group. Higher TR was detected in the CsA group vs the cyclophosphamide (CYC) group, on comparing CsA vs CYC. Overall, findings revealed the efficacy as well as the safety of CsA as a treatment choice for patients with SRNS.